IBDEI0NR ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10692,1,4,0)
 ;;=4^F64.8
 ;;^UTILITY(U,$J,358.3,10692,2)
 ;;=^5003649
 ;;^UTILITY(U,$J,358.3,10693,0)
 ;;=F64.9^^42^477^3
 ;;^UTILITY(U,$J,358.3,10693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10693,1,3,0)
 ;;=3^Gender Dysphoria,Unspec
 ;;^UTILITY(U,$J,358.3,10693,1,4,0)
 ;;=4^F64.9
 ;;^UTILITY(U,$J,358.3,10693,2)
 ;;=^5003650
 ;;^UTILITY(U,$J,358.3,10694,0)
 ;;=G21.19^^42^478^10
 ;;^UTILITY(U,$J,358.3,10694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10694,1,3,0)
 ;;=3^Medication-Induced Parkinsonism,Other
 ;;^UTILITY(U,$J,358.3,10694,1,4,0)
 ;;=4^G21.19
 ;;^UTILITY(U,$J,358.3,10694,2)
 ;;=^5003773
 ;;^UTILITY(U,$J,358.3,10695,0)
 ;;=G21.11^^42^478^13
 ;;^UTILITY(U,$J,358.3,10695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10695,1,3,0)
 ;;=3^Neuroleptic-Induced Parkinsonism
 ;;^UTILITY(U,$J,358.3,10695,1,4,0)
 ;;=4^G21.11
 ;;^UTILITY(U,$J,358.3,10695,2)
 ;;=^5003772
 ;;^UTILITY(U,$J,358.3,10696,0)
 ;;=G24.01^^42^478^15
 ;;^UTILITY(U,$J,358.3,10696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10696,1,3,0)
 ;;=3^Tardive Dyskinesia
 ;;^UTILITY(U,$J,358.3,10696,1,4,0)
 ;;=4^G24.01
 ;;^UTILITY(U,$J,358.3,10696,2)
 ;;=^5003784
 ;;^UTILITY(U,$J,358.3,10697,0)
 ;;=G24.09^^42^478^16
 ;;^UTILITY(U,$J,358.3,10697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10697,1,3,0)
 ;;=3^Tardive Dystonia
 ;;^UTILITY(U,$J,358.3,10697,1,4,0)
 ;;=4^G24.09
 ;;^UTILITY(U,$J,358.3,10697,2)
 ;;=^5003786
 ;;^UTILITY(U,$J,358.3,10698,0)
 ;;=G25.1^^42^478^11
 ;;^UTILITY(U,$J,358.3,10698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10698,1,3,0)
 ;;=3^Medication-Induced Postural Tremor
 ;;^UTILITY(U,$J,358.3,10698,1,4,0)
 ;;=4^G25.1
 ;;^UTILITY(U,$J,358.3,10698,2)
 ;;=^5003792
 ;;^UTILITY(U,$J,358.3,10699,0)
 ;;=G25.71^^42^478^14
 ;;^UTILITY(U,$J,358.3,10699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10699,1,3,0)
 ;;=3^Tardive Akathisia
 ;;^UTILITY(U,$J,358.3,10699,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,10699,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,10700,0)
 ;;=G25.79^^42^478^9
 ;;^UTILITY(U,$J,358.3,10700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10700,1,3,0)
 ;;=3^Medication-Induced Movement Disorder,Other
 ;;^UTILITY(U,$J,358.3,10700,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,10700,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,10701,0)
 ;;=T43.205A^^42^478^4
 ;;^UTILITY(U,$J,358.3,10701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10701,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,10701,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,10701,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,10702,0)
 ;;=T43.205D^^42^478^5
 ;;^UTILITY(U,$J,358.3,10702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10702,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,10702,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,10702,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,10703,0)
 ;;=T43.205S^^42^478^6
 ;;^UTILITY(U,$J,358.3,10703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10703,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,10703,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,10703,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,10704,0)
 ;;=G25.71^^42^478^7
 ;;^UTILITY(U,$J,358.3,10704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10704,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,10704,1,4,0)
 ;;=4^G25.71
